Aurelie S. Leroyer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Aurelie S. Leroyer has a total of 286 co-authors. Here are the top co-authors by number of shared publications:
- Françoise Dignat-George
Aix-Marseille Univ, INSERM, INRAE, Centre de Recherche en CardioVasculaire et Nutrition Marseille, France (P.D., N.O., V.P., F.D.-G., G.H.).
37 shared publications - Nathalie Bardin
Service d’Immunologie, Biogénopôle, Hôpital de la Timone, Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France
29 shared publications - Alexandrine Foucault-Bertaud
Hematology Department, Center for CardioVascular and Nutrition Research C2VN, Faculty of Pharmacy, Timone Campus, Aix-Marseille University, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Recherche Pour L’agriculture, L’alimentation et L’environnement (INRAE), 13005 Marseille, France
26 shared publications - Marcel Blot-Chabaud
Hematology Department, Center for CardioVascular and Nutrition Research C2VN, Faculty of Pharmacy, Timone Campus, Aix-Marseille University, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Recherche Pour L’agriculture, L’alimentation et L’environnement (INRAE), 13005 Marseille, France
24 shared publications - Ahmad Joshkon
Hematology Department, Center for CardioVascular and Nutrition Research C2VN, Faculty of Pharmacy, Timone Campus, Aix-Marseille University, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Recherche Pour L’agriculture, L’alimentation et L’environnement (INRAE), 13005 Marseille, France
21 shared publications - Richard Bachelier
Hematology Department, Center for CardioVascular and Nutrition Research C2VN, Faculty of Pharmacy, Timone Campus, Aix-Marseille University, Institut National de la Santé et de la Recherche Médicale (INSERM), Institut National de Recherche Pour L’agriculture, L’alimentation et L’environnement (INRAE), 13005 Marseille, France
20 shared publications
Latest Publications
- Open Access
- 29 May 2026
- Published by Elsevier in Atherosclerosis
- Vol. 418, 120797
CD146 extracellular vesicles accumulate at atherosclerotic lesions, reducing inflammation and atheroma burden
- 29 May 2026
- Published by Elsevier in Atherosclerosis
- Vol. 418, 120797
Open AccessCD146 extracellular vesicles accumulate at atherosclerotic lesions, reducing inflammation and atheroma burden
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 7 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 7 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 7 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 7 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 12 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 12 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 12 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 12 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 10 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 10 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 10 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 10 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 13 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 13 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 13 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 13 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 1 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 1 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 1 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 1 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 2 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 2 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 2 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 2 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 6 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 6 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 6 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 6 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 5 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 5 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 5 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 5 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- Open Access
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Suppl Figure 11 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 11 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
- 4 February 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Figure 11 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy
Suppl Figure 11 from Soluble CD146 Cooperates with VEGFa to Generate an Immunosuppressive Microenvironment in CD146-Positive Tumors: Interest of a Combined Antibody-Based Therapy